Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees. The company went IPO on 2015-11-11. The firm is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing the Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. The company is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Follow-Up Questions
Who is the CEO of WAVE Life Sciences Ltd?
Dr. Paul Bolno is the President of WAVE Life Sciences Ltd, joining the firm since 2013.
What is the price performance of WVE stock?
The current price of WVE is $8.24, it has decreased 0.78% in the last trading day.
What are the primary business themes or industries for WAVE Life Sciences Ltd?
WAVE Life Sciences Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is WAVE Life Sciences Ltd market cap?
WAVE Life Sciences Ltd's current market cap is $1.3B
Is WAVE Life Sciences Ltd a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for WAVE Life Sciences Ltd, including 6 strong buy, 11 buy, 2 hold, 0 sell, and 6 strong sell
